Itraconazolo Teva (Itraconazole)

Itraconazole is employed to manage fungal infections affecting the skin, nails, and internal organs.

• Dermatophytosis: eradicates dermatophyte organisms, leading to resolution of ringworm and related skin lesions.
• Onychomycosis: penetrates the nail plate to eliminate fungal growth, improving nail appearance and health.
• Candidiasis: treats mucosal and systemic Candida infections, reducing symptoms and preventing dissemination.
• Aspergillosis: inhibits Aspergillus species, aiding recovery in invasive pulmonary disease.
• Blastomycosis: clears Blastomyces dermatitidis infection in pulmonary and disseminated forms.
• Histoplasmosis: combats Histoplasma capsulatum, supporting resolution of acute and chronic disease.

• Itraconazole inhibits the fungal cytochrome P450 enzyme lanosterol 14α‑demethylase, a key step in ergosterol synthesis. By blocking ergosterol production, the drug disrupts fungal cell membrane integrity, leading to impaired growth and eventual cell death across a wide range of pathogenic fungi.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea: mild to moderate stomach upset occurring after oral intake.
• Headache: transient cranial discomfort reported by some patients.
• Rash: skin irritation or mild erythema developing during therapy.

Serious or Rare Side Effects

• Hepatotoxicity: elevated liver enzymes or severe liver injury requiring monitoring.
• Congestive heart failure: fluid retention and worsening of pre‑existing cardiac conditions.
• Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis, demanding immediate discontinuation.

When prescribing itraconazole, clinicians should observe several safety considerations to minimize risk.

• Liver monitoring: Perform baseline and periodic liver function tests because hepatotoxicity can occur.
• Cardiac assessment: Avoid use in patients with existing congestive heart failure due to risk of worsening symptoms.
• Pregnancy caution: Use only if potential benefit justifies potential risk, as safety data are limited.
• Drug interaction review: Evaluate concomitant medications that affect CYP3A4 metabolism.
• Allergy check: Discontinue if hypersensitivity reactions such as rash or angioedema develop.
• Store at room temperature: Keep in original container, protect from moisture and heat.

Itraconazole interacts with several medicines through CYP3A4 modulation and other mechanisms.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): can raise itraconazole levels and increase toxicity.
• Simvastatin and other CYP3A4‑metabolized statins: risk of severe myopathy.
• Ergot alkaloids (e.g., ergotamine): may cause vasospasm and ischemia.
• Quinidine and similar antiarrhythmics: can lead to arrhythmias.
• Oral contraceptives: may reduce efficacy, leading to unintended pregnancy.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower itraconazole concentrations and reduce effectiveness.
• Warfarin: itraconazole can increase INR, requiring closer monitoring.
• Digoxin: possible increase in serum levels, monitor for toxicity.
• Antihistamines (e.g., diphenhydramine): may enhance central nervous system effects.
• HIV protease inhibitors (e.g., indinavir): may require dose adjustment.